https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-302
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Expert Rev Vaccines 2010 Nov;9(11):1275-3022010-11-01 00:00:002019-02-15 09:21:43Use of attenuated paramyxoviruses for cancer therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-17
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Int. J. Oncol. 2010 Nov;37(5):1203-172010-11-01 00:00:002021-11-15 17:00:11Optimization studies for the coupling of bispecific antibodies to viral anchor molecules of a tumor vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-2
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Gan To Kagaku Ryoho 2010 Nov;37(12):2240-22010-11-01 00:00:002019-02-15 08:52:01[WT1 peptide pulsed dendritic cell therapy with activated T lymphocytes therapy for advanced cancers]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-11-01 / Singapore Med J 2010 Nov;51(11):e187-90
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-11-01 / Singapore Med J 2010 Nov;51(11):e187-902010-11-01 00:00:002010-11-01 00:00:00Palliation of recurrent myxofibrosarcoma with radiotherapy and hyperthermia
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-47
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-28 / Expert Opin Biol Ther 2010 Dec;10(12):1637-472010-10-28 00:00:002019-02-15 08:40:13Personalized cancer vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-28 / Blood 2011 Jan;117(2):393-402
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-28 / Blood 2011 Jan;117(2):393-4022010-10-28 00:00:002019-02-15 08:50:45Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-27 / Vaccine 2010 Nov;28(51):8162-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-27 / Vaccine 2010 Nov;28(51):8162-82010-10-27 00:00:002019-02-15 08:40:11Vaccination with dendritic cells charged with apoptotic/necrotic B16 melanoma induces the formation of subcutaneous lymphoid tissue
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-22 / BMC Cancer 2010 Oct;10:578
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-22 / BMC Cancer 2010 Oct;10:5782010-10-22 00:00:002019-02-15 08:48:06Chemokine-mediated distribution of dendritic cell subsets in renal cell carcinoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-20 / Cancer Immunol. Immunother. 2011 Jan;60(1):123-31
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-20 / Cancer Immunol. Immunother. 2011 Jan;60(1):123-312010-10-20 00:00:002019-02-15 08:49:23Resistance to the proapoptotic effects of interferon-gamma on melanoma cells used in patient-specific dendritic cell immunotherapy is associated with improved overall survival
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2010-10-13 / Int. J. Biol. Sci. 2010 Oct;6(7):639-48
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2010-10-13 / Int. J. Biol. Sci. 2010 Oct;6(7):639-482010-10-13 00:00:002019-02-15 08:47:47Comparative analysis of cytotoxic T lymphocyte response induced by dendritic cells loaded with hepatocellular carcinoma -derived RNA or cell lysate
